PDCD1 and non-small cell lung carcinoma: The Food and Drug Administration (FDA) approved programmed cell death 1 (PD-1) inhibitors such as nivolumab and pembrolizumab for the treatment of stage IV non-small cell lung cancers (NSCLC) in 2014 [1].